C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.905
-0.005 (-0.26%)
Jan 2, 2026, 11:59 AM EST - Market open
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $11.23M in the quarter ending September 30, 2025, a decrease of -26.90%. This brings the company's revenue in the last twelve months to $30.11M, down -10.57% year-over-year. In the year 2024, C4 Therapeutics had annual revenue of $35.58M with 71.44% growth.
Revenue (ttm)
$30.11M
Revenue Growth
-10.57%
P/S Ratio
4.52
Revenue / Employee
$273,709
Employees
110
Market Cap
184.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.58M | 14.83M | 71.44% |
| Dec 31, 2023 | 20.76M | -10.34M | -33.25% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CCCC News
- 5 weeks ago - Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss - Seeking Alpha
- 5 weeks ago - C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 2 months ago - C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - GlobeNewsWire
- 3 months ago - C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 3 months ago - C4 Therapeutics, Inc. - Special Call - Seeking Alpha
- 3 months ago - C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting - GlobeNewsWire